#SecondaryProgressiveMultipleSclerosis - Twitter Hashtag

7 months ago

#SecondaryProgressiveMultipleSclerosis (#SPMS) is a form of #MS that evolves from #RelapsingRemittingMultipleSclerosis (#RRMS) over time. Learn more here about the transition, as well as potential symptoms and treatment options:https://t.co/ZGZl6dqrgV

0

4

0

2

270

MyMSTeam @MyMSTeam

7 months ago

Symptoms of #SecondaryProgressiveMultipleSclerosis depend on which parts of the central nervous system are impacted. Problems with balance and walking are among the most common symptoms reported by people with #SPMS. Learn more:https://t.co/hwhn61erkO

0

5

0

1

197

MyMSTeam @MyMSTeam

10 months ago

Symptoms of #SecondaryProgressiveMultipleSclerosis depend on which parts of the central nervous system are impacted. Problems with balance and walking are among the most common symptoms reported by people with #SPMS. Learn more:https://t.co/hwhn61erkO

0

2

0

102

Rare Disease Advisor @RareDisease_Adv

over 3 years ago

A recent study has revealed that a subgroup of young patients with #SecondaryProgressiveMultipleSclerosis (#SPMS) had a higher frequency of #RadiologicalDiseaseActivity unrelated to its #ClinicalSymptomatology. @NeuroKarger https://t.co/mZdoypwIXs #MultipleSclerosis #NeuroTwitter

0

3

2

0

178

Pharmaceutical Market Europe @PMLiVEcom

over 3 years ago

Tiziana’s foralumab shows continued clinical improvement in secondary progressive MS https://t.co/Qt5gfmaRvv #TizianaLifeSciences #secondaryprogressivemultiplesclerosis

0

2

0

128

Rare Disease Advisor @RareDisease_Adv

over 3 years ago

Nasal administration of #Foralumab showed positive clinical effects for 2 patients with nonactive #SecondaryProgressiveMultipleSclerosis (#SPMS), according to findings presented at the Congress of the @ECTRIMS https://t.co/PkOEuMcrmy #MSCommunity #MS #MultipleSclerosis #ECTRIMS

0

12

4

0

Pharmaceutical Market Europe @PMLiVEcom

almost 4 years ago

Tiziana’s Foralumab shows promise in second patient with secondary progressive MS https://t.co/4xoHxAAz1F #TizianaLifeSciences #secondaryprogressivemultiplesclerosis

0

16

4

0

ACF Equity Research

@ACFER01

almost 4 years ago

.@TizianaLS Nasdaq: $TLSA ~▲2.17% on continued clinical improvements in 2nd patient w/ #SecondaryProgressiveMultipleSclerosis (SPMS) after 6 mths of dosing w/ intranasal Foralumab. Global #multiplesclerosisdrugs mkt size @ $33.17bn by 2029E. #ACFinsight https://t.co/hV5flzx5WY

ACFER01's tweet photo. .@TizianaLS Nasdaq: $TLSA ~▲2.17% on continued clinical improvements in 2nd patient w/ #SecondaryProgressiveMultipleSclerosis (SPMS) after 6 mths of dosing w/ intranasal Foralumab. Global #multiplesclerosisdrugs mkt size @ $33.17bn by 2029E. #ACFinsight https://t.co/hV5flzx5WY https://t.co/mgRH7laa9A

0

5

2

0

Audible Silence #FBPE Sara Avila #IndyWales @SeaCasa1

almost 4 years ago

So THIS happened this morning... #MS #MSisms #SecondaryProgressiveMultipleSclerosis

2

3

0

Paul @griffax09

over 4 years ago

Trying to take a selfie when I have spasms in my hand/fingers.... #SecondaryProgressiveMultipleSclerosis

0

11

0

Paul @griffax09

over 5 years ago · Wibsey

Proud to be a participant in this trial. #MSstat2 #SecondaryProgressiveMultipleSclerosis

MS Society UK @mssocietyuk

over 5 years ago

Our MS-STAT2 trial is testing if simvastatin (a cholesterol-lowering drug) can slow disability progression for people with secondary progressive MS. Trial Staff and participants have kept fighting to keep the research going throughout the pandemic: https://t.co/75kdPbiuxd